In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET

被引:24
作者
Conti, Peter S. [1 ]
Bading, James R. [1 ]
Mouton, Peter P. [2 ]
Links, Jonathan M. [3 ]
Alauddin, Mian M. [1 ]
Fissekis, John D. [1 ]
Ravert, Hayden T. [3 ]
Hilton, John [3 ]
Wong, Dean F. [3 ]
Anderson, James H. [3 ]
机构
[1] Univ So Calif, PET Imaging Sci Ctr, Dept Radiol, Los Angeles, CA 90033 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21218 USA
[3] Johns Hopkins Med Inst, Dept Radiol & Radiol Sci, Baltimore, MD 21218 USA
关键词
D O I
10.1016/j.nucmedbio.2007.09.003
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Noncatabolized thymidine analogs are being developed for use in imaging DNA synthesis. We sought to relate a labeling index measured by immunohistochemical staining bromodeoxyuridine (BUdR) technique to the uptake of C-11 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) measured with positron emission tomography (PET) in a brain tumor model. Methods: Adult beagles (n=8) with implanted brain tumors received [C-11]FMAU and dynamic imaging with arterial sampling. Six dogs were then infused with BUdR (200 mg/m(2)) and sacrificed. Tumor time-activity curves (TACs) obtained from computed-tomography-defined regions of interest were corrected for partial volume effects and crosstalk from brain tissue. Tissue was analyzed for the percentage of tumor volume occupied by viable cells and by viable cells in S-phase as identified by BUR staining. PET/[C-11]FMAU and BUR were compared by linear regression analysis and analysis of variance, as well as by a nonparametric rank correlation test. Results: Tumor standardized uptake values (SUVs) and tumor-to-contralateral-brain uptake ratios at 50 min were 1.6+/-0.4 and 5.5+/-1.2 (n=8; mean+/-S.E.M.), respectively. No C-11-labeled metabolites were observed in the blood through 60 min. Tumor TACs were well described with a three-compartment/four-parameter model (k(4)=0) and by Patlak analysis. Parametric statistical analysis showed that FMAU clearance from plasma into tumor Compartment 3 (K-FMAU) was significantly correlated with S-phase percent volume (P=.03), while tumor SUV was significantly correlated with both S-phase percent volume and cell percent volume (P=.02 and .03, respectively). Patlak slope, KFMAU and tumor SUV were equivalent with regard to rank correlation analysis, which showed that tumor uptake and trapping of FMAU were correlated with the volume density of dividing cells (P=.0003) rather than nondividing cells (P=.3). Conclusions: Trapping of [C-11]FMAU correlated with tumor growth rate, as measured by direct tissue analysis with BUR in a canine brain tumor model, suggesting that [C-11]FMAU is useful for the imaging of cell proliferation in cancers. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:131 / 141
页数:11
相关论文
共 41 条
[11]   Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? [J].
Colozza, M ;
Azambuja, E ;
Cardoso, F ;
Sotiriou, C ;
Larsimont, D ;
Piccart, MJ .
ANNALS OF ONCOLOGY, 2005, 16 (11) :1723-1739
[12]  
Conti PS, 2002, J NUCL MED, V43, p26P
[13]   SYNTHESIS OF 2'-FLUORO-5-[C-11]-METHYL-1-BETA-D-ARABINOFURANOSYLURACIL ([C-11]-FMAU) - A POTENTIAL NUCLEOSIDE ANALOG FOR IN-VIVO STUDY OF CELLULAR PROLIFERATION WITH PET [J].
CONTI, PS ;
ALAUDDIN, MM ;
FISSEKIS, JR ;
SCHMALL, B ;
WATANABE, KA .
NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (06) :783-789
[14]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF C-11 LABELED THYMIDINE AND ITS MAJOR CATABOLITES FOR CLINICAL PET STUDIES [J].
CONTI, PS ;
HILTON, J ;
WONG, DF ;
ALAUDDIN, MM ;
DANNALS, RF ;
RAVERT, HT ;
WILSON, AA ;
ANDERSON, JH .
NUCLEAR MEDICINE AND BIOLOGY, 1994, 21 (08) :1045-1051
[15]   COMPARISON OF THE SUBSTRATE SPECIFICITIES OF HUMAN THYMIDINE KINASE-1 AND KINASE-2 AND DEOXYCYTIDINE KINASE TOWARD ANTIVIRAL AND CYTOSTATIC NUCLEOSIDE ANALOGS [J].
ERIKSSON, S ;
KIERDASZUK, B ;
MUNCHPETERSEN, B ;
OBERG, B ;
JOHANSSON, NG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 176 (02) :586-592
[16]   Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy--glucose in positron emission tomography for colorectal cancer [J].
Francis, DL ;
Visvikis, D ;
Costa, DC ;
Arulampalam, THA ;
Townsend, C ;
Luthra, SK ;
Taylor, I ;
Ell, PJ .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (07) :988-994
[17]   Early response assessment using 3′-Deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma [J].
Herrmann, Ken ;
Wieder, Hinrich A. ;
Buck, Andreas K. ;
Schoeffel, Marion ;
Krause, Bernd-Joachim ;
Fend, Falko ;
Schuster, Tibor ;
zum Bueschenfeld, Christian Meyer ;
Wester, Hans-Juergen ;
Duyster, Justus ;
Peschel, Christian ;
Schwaiger, Markus ;
Dechow, Tobias .
CLINICAL CANCER RESEARCH, 2007, 13 (12) :3552-3558
[18]  
HIGASHI K, 1993, J NUCL MED, V34, P414
[19]   VARIABILITY IN THE PROLIFERATIVE POTENTIAL OF HUMAN GLIOMAS [J].
HOSHINO, T ;
NAGASHIMA, T ;
CHO, KG ;
DAVIS, RL ;
DONEGAN, J ;
SLUSARZ, M ;
WILSON, CB .
JOURNAL OF NEURO-ONCOLOGY, 1989, 7 (02) :137-143
[20]   Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18 F]fluorothymidine positron emission tomography:: The effect of cisplatin on a fibrosarcoma tumor model in vivo [J].
Leyton, J ;
Latigo, JR ;
Perumal, M ;
Dhaliwal, H ;
He, QM ;
Aboagye, EO .
CANCER RESEARCH, 2005, 65 (10) :4202-4210